Baird Maintains an 'Outperform' on Affymax, Inc. (AFFY); So You’re Tellin’ Me There’s a Chance

Baird maintains an 'Outperform' on Affymax, Inc. (NASDAQ: AFFY) price target of $13.00.

Baird analyst says, "Incrementally positive on AFFY shares after FDA released its briefing documents in advance of Wednesday’s ODAC panel review of peginesatide. We view FDA questions and interpretation of peginesatide’s Phase III data set as much more favorable and forgiving than would have been expected, given the safety signal seen in pre-dialysis patients when the data were released last year. With the stock still pricing in very little chance of approval, we continue to like the risk/reward here going into Wednesday’s review."

For an analyst ratings summary and ratings history on Affymax, Inc. click here. For more ratings news on Affymax, Inc. click here.

Shares of Affymax, Inc. closed at $5.25 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• McGraw Hill (MH) PT Raised to $15 at UBS